Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes

  title={Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes},
  author={Nisa M. Maruthur and E. Tseng and S. Hutfless and L. Wilson and Catalina Suarez-Cuervo and Zackary Berger and Y. Chu and E. Iyoha and J. Segal and S. Bolen},
  journal={Annals of Internal Medicine},
  • Nisa M. Maruthur, E. Tseng, +7 authors S. Bolen
  • Published 2016
  • Medicine
  • Annals of Internal Medicine
  • Type 2 diabetes and its complications are a substantial public health burden, affecting 9.3% of the U.S. adult population (1, 2). Most patients with type 2 diabetes eventually require glucose-lowering pharmacologic therapy, with a goal of reducing long-term complications. More than 7 classes of diabetes medications, which differ in their effects on glucose-lowering, safety, and other important outcomes, are recommended as first- or second-line therapy (3, 4). The Agency for Healthcare Research… CONTINUE READING
    295 Citations
    Glycemic Therapy for Type 2 Diabetes: Choices Expand, Data Lag Behind
    • 1
    Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes
    • 28
    • Highly Influenced
    Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?
    • PDF
    Drugs for Treatment of Diabetes Mellitus
    • 1


    10-year follow-up of intensive glucose control in type 2 diabetes.
    • 4,421
    • PDF
    Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
    • 2,662
    • Highly Influential
    • PDF
    Effects of intensive glucose lowering in type 2 diabetes.
    • 4,662
    • PDF